Replies to post #323157 on Avid Bioservices Inc (CDMO)

[biopharm]

#9 PS Targeting patent - Johns Hopkins -

....the list continues to grow with many infringing upon PS Targeting patents

____

Chimeric proteins with phosphatidylserine binding domains
WO 2006096828 A2
ABSTRACT
Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidyl serine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.

...
...
https://www.google.com/patents/WO2006096828A2

[biopharm]

#7 #8 PS Targeting Patent - Roche BMS - also stepping on the patents(will have to update the complete list from prior post...)

So now with about 8 patents filed with need of PS Targeting licensing, how does that explain the "residual value" statement made by Renegade Roger Lias ? It does not add up......especially where Peregrine Dr Freimark collaborators included Pfizer and how many more dozens of non Disclosed collaborations would the CEO and Bard be trying to silence ?

I think whatever plan of winding down R&D should be given to shareholders ? Did they call and silence Dr Jedd Wolchok....MSK...NCCN....????